TY - JOUR
T1 - Rhabdomyosarcoma of the female urogenital tract
AU - Hays, Daniel M.
AU - Raney, R. Beverly
AU - Lawrence, Walter
AU - Gehan, Edmund A.
AU - Soule, Edward H.
AU - Tefft, Melvin
AU - Maurer, Harold M.
AU - Intergroup Rhabdomyosarcoma Study Commitee, Rhabdomyosarcoma Study Commitee
N1 - Funding Information:
From the Intergroup Rhabdomyosarcoma Committee, representing Cancer and Acute Leukemia Group B, Children's Cancer Study Group and Southwest Oncology Group, Denman Hammond, M.D., Robert Lindberg, M.D., Harold M. Maurer, M.D., William Newton, M.D., Abdelsalam Ragab, M.D., Frederick Ruymann, M.D., William M. Crist, M.D., and Ruth Heyn, M.D. Supported by U.S. Public Health Service Grants CA 03735, CA 04646, CA 10214, CA 16843, CA 13539, CA 16118, and CA 08128. Presented before the Twelfth Annual Meeting of the American Pediatric Surgical Association together with the British Association of Paediatric Surgeons, Tarpon Springs, Florida, April 29-May 2, 198l. Address reprint requests to Daniel M. Hays, M.D., Chil-drens Hospital of Los Angeles, P.O. Box 54700, Terminal Annex, Los Angeles, Calif. 90054. 9 1981 by Grune & Stratton, Inc. 00 2 2-3 468/81/1606~9011 $01.00/0
PY - 1981/12
Y1 - 1981/12
N2 - During the initial 6 yr (1972-1978) of the Intergroup Rhabdomyosarcoma Study (IRS), 27 patients with rhadomyosarcoma of the female urogenital tract were treated, and the results of therapy were evaluated on the basis of 3-7 yr of observation. By primary site these tumors were: bladder, 14; vagina, 9; vulva, 2; and cervix uterus, 2. Twenty-three patients presented with localized tumors; the four remaining patients (1 bladder, 1 vagina, and 2 cervix) had distant metastases at diagnosis. Two patients with bladder tumors underwent pelvic exenteration, local irradiation, and chemotherapy (2 yr), and were without relapse. Ten patients were treated by partial cystectomy and postoperative chemotherapy (with or without local irradiation) and fatal recurrence occurred in three. The remaining seven patients are disease-free for 36-74 mo (mean, 51.8 mo). Six of the eight patients with nondisseminated vaginal tumors were treated by initial pelvic exenteration (2), hysterectomy-vaginectomy (2), or hemivaginectomy (2). All received postoperative chemotherapy and three received local irradiation. Delayed hysterectomy-vaginectomy after primary chemotherapy was performed in the two additional patients with vaginal tumors. Relapse has occurred in one of these eight patients with localized vaginal disease. The remaining seven have been observed for 3-5.5 yr (mean, <4 yr). Two patients with vulval lesions treated by a combined therapy regimen are without recurrence. Our conclusion is that chemotherapy has significantly increased survival in females with urogenital tract rhabdomyosarcomas.
AB - During the initial 6 yr (1972-1978) of the Intergroup Rhabdomyosarcoma Study (IRS), 27 patients with rhadomyosarcoma of the female urogenital tract were treated, and the results of therapy were evaluated on the basis of 3-7 yr of observation. By primary site these tumors were: bladder, 14; vagina, 9; vulva, 2; and cervix uterus, 2. Twenty-three patients presented with localized tumors; the four remaining patients (1 bladder, 1 vagina, and 2 cervix) had distant metastases at diagnosis. Two patients with bladder tumors underwent pelvic exenteration, local irradiation, and chemotherapy (2 yr), and were without relapse. Ten patients were treated by partial cystectomy and postoperative chemotherapy (with or without local irradiation) and fatal recurrence occurred in three. The remaining seven patients are disease-free for 36-74 mo (mean, 51.8 mo). Six of the eight patients with nondisseminated vaginal tumors were treated by initial pelvic exenteration (2), hysterectomy-vaginectomy (2), or hemivaginectomy (2). All received postoperative chemotherapy and three received local irradiation. Delayed hysterectomy-vaginectomy after primary chemotherapy was performed in the two additional patients with vaginal tumors. Relapse has occurred in one of these eight patients with localized vaginal disease. The remaining seven have been observed for 3-5.5 yr (mean, <4 yr). Two patients with vulval lesions treated by a combined therapy regimen are without recurrence. Our conclusion is that chemotherapy has significantly increased survival in females with urogenital tract rhabdomyosarcomas.
KW - Rhabdomyosarcoma
KW - female urogenital rhabdomyosarcoma
UR - http://www.scopus.com/inward/record.url?scp=0019851391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019851391&partnerID=8YFLogxK
U2 - 10.1016/S0022-3468(81)80828-7
DO - 10.1016/S0022-3468(81)80828-7
M3 - Article
C2 - 7338762
AN - SCOPUS:0019851391
SN - 0022-3468
VL - 16
SP - 828
EP - 834
JO - Journal of pediatric surgery
JF - Journal of pediatric surgery
IS - 6
ER -